I-Corps: Photopharmacology

I-Corps：光药理学

• 批准号: 1744405
• 负责人: Jared Toettcher
• 金额: $ 5万
• 依托单位: Princeton University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-15 至 2018-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1744405&HistoricalAwards=false
• 关键词: Corps; Photopharmacology

The broader impact/commercial potential of this I-Corps proposal lies in its potential to enable a new degree of precise control over medicines that could substantially increase the efficacy of many current therapeutics as well as re-invigorate the potential of drugs that previously failed clinical trials owing to unfavorable toxicity profiles. By enabling clinician-defined control over when and where a drug is active in the body, this technology has the potential to improve the efficacy of on-target effects while mitigating toxic side-effects that decrease patients' quality of life. Not only do pharmaceutical companies invest significant time and money honing the pharmacokinetics of each drug they bring to market, once a drug is in the clinic, companies have no means of altering the final product to adapt to the individual needs of patients. This project could streamline the costly process of tuning drugs' pharmacokinetics, while also improving their efficacy for a broader patient population.This I-Corps project is based on the combination of two enabling technologies. It combines advances in molecular engineering to create molecules whose activity can be controlled using different wavelengths of light, with a process for identifying light-responsive molecules that possess specific therapeutic properties of interest. Suites of light-switchable molecules have been designed in non-therapeutic contexts as a proof-of-concept, though these technologies have not yet been applied to therapeutics. A research pipeline for applying this technology to medically important molecules is being developed.

该I-Corps提案的更广泛的影响/商业潜力在于它的潜力是使对药物的新程度的精确控制能够实质上提高许多当前治疗剂的疗效，并重新侵害了以前因不利毒性概况而导致临床试验的药物的潜力。通过使临床医生对药物在体内活跃的何时何地的控制，该技术有可能提高靶向效应的疗效，同时减轻降低患者生活质量的毒性副作用。制药公司不仅投入了大量时间和金钱来磨练他们将每种药物的药代动力学磨练，一旦药物进入诊所，公司就无法改变最终产品以适应患者的个人需求。该项目可能会简化调整药物的药代动力学的昂贵过程，同时也提高其对更广泛的患者人群的疗效。此I-Corps项目基于两种启用技术的组合。它结合了分子工程的进步，以创建可以使用不同的光波长来控制活性的分子，并通过鉴定具有特定感兴趣的治疗特性的光反应分子的过程。尽管尚未将这些技术应用于治疗疗法，但在非治疗环境中设计了轻便分子的套件。正在开发用于将该技术应用于医学重要分子的研究管道。